A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

This study has been completed.
Sponsor:
Information provided by:
Neurotech Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00447993
First received: March 9, 2007
Last updated: April 12, 2011
Last verified: April 2011

March 9, 2007
April 12, 2011
January 2007
October 2009   (final data collection date for primary outcome measure)
The primary outcome is the change in best-corrected visual acuity (BCVA) using the Electronic Visual Acuity (EVA) technology at month 12. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
The primary outcome is the change in best-corrected visual acuity (BCVA) using the Electronic Visual Acuity (EVA) technology at month 12.
Complete list of historical versions of study NCT00447993 on ClinicalTrials.gov Archive Site
Longer-term observations of change in visual acuity, disease modification, BCVA, ERG, optical coherence tomography, inflammation, and vision-related quality of life(NEI-VFQ25). [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Longer-term observations of change in visual acuity, disease modification, BCVA, ERG, optical coherence tomography, inflammation, and vision-related quality of life(NEI-VFQ25).
Not Provided
Not Provided
 
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome

The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II & III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect our ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision.

The implant is a small capsule that contains human retinal pigment epithelium cells. These cells have been given the ability to make CNTF and release it through the capsule membrane into the surrounding fluid. This study will look at the effect of the implant on vision loss by retinitis pigmentosa, Usher type II & III, and Choroideremia. In this study, two different CNTF dose levels will be used: a high dose and a low dose in one eye, as well as a sham (or placebo) surgery in the other eye.

This study will involve about 16 visits over 1½ years for specific tests of the participant's vision and health. These visits may include visual exams, blood draw for laboratory testing, brief medical history and exam, and occasionally a questionnaire (survey), in addition to the visit for the surgical procedures. The primary effectiveness outcome for this study will be a visual acuity score one year after the implant surgery. There will be about 13 centers participating in this study, and up to 60 people enrolled across the US. Each participant joining the study who has completed initial screening will then be scheduled to have a brief surgical procedure performed on each eye, one of which will include a very small cell-filled implant. Follow-up visits for repeat assessments will be required regularly to determine if the implant being tested is safe and effective for use to treat RP.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Retinitis Pigmentosa
  • Drug: NT-501
    High Dose
  • Drug: NT-501
    Low Dose
  • Experimental: 1 NT-501
    High Dose Implant
    Intervention: Drug: NT-501
  • Experimental: 2 NT-501
    Low Dose Implant
    Intervention: Drug: NT-501

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

Criteria for patients to qualify for the study include, but are not limited to:

  • Over 18 years of age, and less than 68 years of age
  • Diagnosis of retinitis pigmentosa, Usher Syndrome Type 2 or 3 or Choroideremia
  • Visual acuity no better than 20/63 and no worse than 20/320
  • Reduced electrical responses from the retina (ERG) and loss of peripheral vision

Exclusion Criteria:

The following criteria will exclude patients from the study:

  • Pregnant or lactating females, or females planning to become pregnant during the study or not using an acceptable method of contraception.
  • Retinitis pigmentosa caused by a classic syndrome, including Usher Type I
  • Other eye diseases including advanced cataract.
  • Chronic systemic disease requiring continuous treatment with systemic steroids, immunosuppressive medications or insulin.
Both
18 Years to 68 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00447993
CNTF 3
Yes
Weng Tao, MD, PhD, Neurotech USA
Neurotech Pharmaceuticals
Not Provided
Study Director: Weng Tao, M.D., PhD Neurotech Pharmaceuticals
Neurotech Pharmaceuticals
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP